Resolution Pharmaceuticals inks deals

Article

Radiopharmaceutical developer Resolution Pharmaceuti-cals of Mississauga,Ontario, has entered into two R&D collaborations with Canadianinstitutes to develop new imaging agents. Both deals have thesupport of Canadian research agencies. In the first

Radiopharmaceutical developer Resolution Pharmaceuti-cals of Mississauga,Ontario, has entered into two R&D collaborations with Canadianinstitutes to develop new imaging agents. Both deals have thesupport of Canadian research agencies.

In the first deal, Resolution and the Alberta Peptide Institutewill receive up to $200,000 from the National Research Council'sIndustrial Research Assistance Program to investigate new radiopharmaceuticalsto image bacterial and fungal infections.

In the second deal, Resolution and the Ontario Cancer Centerreceived a $50,000 grant from the Medical Research Council ofCanada to research compounds to be used in functional medicalimaging that could also be used to aid disease treatment suchas chemotherapy.

Resolution Pharmaceuticals is a joint venture between Canadianradioisotope producer Nordion International and Allelix Biopharmaceuticals.The company's peptide-based radiopharmaceutical for imaging inflammatorydisease completed phase I clinical testing earlier this year (SCAN1/17/96).

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.